ACRV
Acrivon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.85
+8.82%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.45
- Revenue estimate
- $504.3K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.43
- EPS estimate
- -$0.50
- Revenue actual
- —
- Revenue estimate
- $386.3K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +8.0%
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.50 | -$0.43 | Beat 14.38% | — |
| May 13, 2026 | -$0.49 | -$0.49 | In line | — |
| Mar 19, 2026 | -$0.49 | -$0.49 | In line | — |
| Nov 13, 2025 | -$0.57 | -$0.47 | Beat 17.54% | — |
| Aug 13, 2025 | -$0.57 | -$0.55 | Beat 3.51% | — |
| May 14, 2025 | -$0.57 | -$0.51 | Beat 10.53% | — |
| Mar 27, 2025 | -$0.69 | -$0.60 | Beat 13.04% | — |
| Nov 9, 2023 | -$0.72 | -$0.66 | Beat 8.33% | — |
| Aug 11, 2023 | -$0.68 | -$0.63 | Beat 7.35% | — |
| Nov 14, 2022 | -$2.44 | -$0.47 | Beat 80.78% | — |
| Aug 14, 2022 | — | -$0.44 | — | — |
| May 15, 2022 | — | -$0.56 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026